- Adherence to ritonavir-boosted ombitasvir, paritaprevir, and dasabuvir (PrOD) ± ribavirin (RBV) is lower among opioid substitution therapy (OST) recipients, but has no discernible effect on treatment completion or HCV-1 clearance rates.
Why this matters
- Findings support use of direct-acting antivirals in this population.
- Post-hoc analysis of data for 4747 patients receiving PrOD±RBV for HCV-1 across 12 phase 2, 3, and 3b clinical trials; 149 (3%) were receiving OST at baseline.
- Efficacy defined as sustained virologic response at 12 weeks posttherapy (SVR12).
- Funding: AbbVie.
- OST recipients vs nonrecipients were more often infected with genotype 1a (82% vs 52%) and treatment-naive (76% vs 61%); cirrhosis prevalence was similar between groups (17% vs 18%).
- OST recipients were less likely to have ≥90% treatment adherence (88% vs 97%; P<.001 style="list-style-type:circle;">
- Difference driven by PrOD+RBV subset, showing lower adherence to both PrOD (92% vs 99%; P<.001 and rbv vs p>
- Small OST sample.
- Exclusion of patients with ongoing drug use.
- Less adherence data captured for OST recipients (81% vs 91%).